Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIB003 (Lerodalcibep) Long-Term Extension in Hypercholesterolemia
NCT03847974Phase 2Completed
- Sponsor
- LIB Therapeutics
- Start
- Feb 2019
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lerodalcibep in hypercholesterolemia, sponsored by LIB Therapeutics. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 52 weeks. Started Feb 2019; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03847974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847974.